joan G L

Initio Barcino

[Jordi Remon @JordiRemon]

Treatment landscape of early-stage NSCLC is evolving very fast. We review current SoC with IO and targeted therapies(TT) and future challenges:
-Neoadj vs periop?
-IO in borderline resectable
-How to ⬆️pCR
-Role of TT..
@peters_solange @g_mountzios
https://t.co/d7DXBbYkXI

[Jordi Remon @JordiRemon]

Treatment landscape in 🧬EGFRex20ins and HER2-deregulated NSCLC🫁 is evolving rapidly with several challenges: new drugs, access, sequential treatment, resist., efficacy across stages… In this review we provide current data and challenges @LodovicaZullo
https://t.co/xmopO4Muo1

[Jordi Remon @JordiRemon]

WUKONG28: 1st line sunvozertinib (300 mg) improved PFS vs CT in mNSCLC & EGFRex20ins. First positive trial. Qx🧐
-dose:200 or 300? FDA approved 200 in 2L. Toxicity!
-TKI alone or TKI+CT specially for EGFR20ins far-loop?
-Other trials ongoing, crowded space
-Best sequence? #ASCO26

[Jordi Remon @JordiRemon]

Patients with uncommonEGFRmutNSCLC an unmet need. Amiv + Lazertinib impressive OS of 41 mo.🧐
-New dose formulations of ami to mitigate toxicity
-Surprising this combo in uEGFRm not report TVE
-TKIs ongoing: firmonertinib, BDTX-1535. Better 1st line?
-Intracranial?#ASCO26

[Jordi Remon @JordiRemon]

Sacituzumab tirumutecan +pembro ⬇️ 65% risk of PD vs pembro alone in PDL1>1% mNSCLC in interim analys including Sq!!
Crowded space of ADC antiTROP2 in 1st line combined with IO
Geographical representation of the trial (only in China) may limit regulatory approval by FDA?#ASCO26

[Jordi Remon @JordiRemon]

Krescendo 170 trial
Supports in 1st L in KRASG12Cmut NSCLC we can avoid platinum-CT as divarasib + pembro reported impressive outcomes in PDL1+ and PDL1- with mPFS in PDL1 + of 19.3 mo. Benefit mainly in high PDL1. Need data from KRESCENDO2 to confirm this important data #ASCO26

[Jordi Remon @JordiRemon]

1stL in KRASG12Cmut NSCLC will be crowded and complex. Elisrasib, another KRASG12Coff inh, reported activityn in 1stL alone and combo with pembro. Next future: how to decide intensification? Based on PDL1, comut, brain met status🤯.Will not be easy!! To icity is a concern #ASCO26

[Jordi Remon @JordiRemon]

Crowded Space for antiTROP2 ADC with IO in 1stLNSCLC. OptitroptLung05 Trial, only China, report ⬇️65% risk of disease PD 65% with SaciTirua + pembro vs pembro in PDL1+ NSCLC. Geographical representation vs access to innovation as no approved by worldwide authorities? #ASCO26

[Jordi Remon @JordiRemon]

KRAS G12-mutant NSCLC: a practical guide for clinicians
We review current evidence on treatment strategies to provide an up-to-date about this topic to clinicians and discussing challenges. @HendriksLizza @stephanieplsaw @BRicciutiMD La Cava M Borgeaud
https://t.co/RVNMFzoYw0

[Jordi Remon @JordiRemon]

Fantastic presentation by Prof Jassem about roles of Pharma / Academia in drug development.
The strength of the EORTC Lung Cancer Group lies in its multidisciplinary to design academic studies with drugs developed by pharma aiming to identify optimal drug for groups of patients

[Jordi Remon @JordiRemon]

Great discussions at the EORTC Lung Cancer Group meeting in Gdańsk. A real privilege to work with such a collaborative and forward-thinking community—especially encouraging to see new voices actively contributing to study design and research priorities. You are welcome!! #EORTC

[Jordi Remon @JordiRemon]

Excited to be in Gdansk for the @EORTC Lung Cancer Group Spring Meeting. Proud to see so many early-career investigators leading discussions, challenging ideas, and shaping the future of thoracic oncology. The next generation is already here. #LungCancer #Oncology #EORTC

[Jordi Remon @JordiRemon]

More drugs ≠ better access.Despite a crowded NSCLC landscape,global inequities persist—driven by cost, fragmented regulation,and trial design. Our publication argues dose optimization could be a path toward more sustainable and equitable cancer care.
doi:10.1200/EDBK-26-517100

[Jordi Remon @JordiRemon]

Setidegrasib, novel KRAS G12D protein degrader reporting clinical meaningful outcomes with PFS of 11.2 m in 2/3L
However there are KRAS G12D ON or ON/OFF inhibitors with activity. How to decide best drug? Based on safety, intracranial activity and impact of comutations? #ELCC26

[Jordi Remon @JordiRemon]

Adagrasib 600 mg BID in 2nd line is feasible for older patients
(>70years) in KRAS G12C NSCLC but not for pts withPS2. In this population, 30% of ttx discont for AEs. Could lower doses (400 mg BID) reach primary endpoint in population? Doses of inhibitors matter! #ELCC26

[Jordi Remon @JordiRemon]

In ph2, KRAS G12C off inhibitors in combination with IO in 1st line looks promising in high PDL1 KRAS G12Cm NSCLC. More modest activity when combine with CTIO. Crowded space with at least 7 ph3 trials evaluating these strategies. How to select pts for intensification? #ELCC26

[Jordi Remon @JordiRemon]

Are we ready for deintensification adjuvant IO in early-stage 🫁? In the future molecular and pathological parameters will guide our decisions? For pCR after induction CTIO we can discuss surveillance and in no-pCR probably continuing the same IO not the besst approach #ELCC26

[Jordi Remon @JordiRemon]

Zongertinib in HER2mutant advanced NSCLC reported mPFS in 1st line of 14.4 mo with intracranial activity. Strong arguments to become a new SoC despite small sample size. It is FDA approved but not EMA. 🤦🏻This may impact enrollment in ongoing ph3 trial Zong vs CTIO 1L? #ELCC26

[Jordi Remon @JordiRemon]

Looking forward to EORTC LCG spring meeting:Gdansk 16-18 April hosted by Pr Dziadziuszko & Dr Bandura + Young Early Career Investigators meeting on 16 April led by the fantastic @RobertoFerrara and Dr Prisciandaro. The future of EU🫁 oncology in EU is bright!Stay tuned⭐️⭐️@EORTC

[Jordi Remon @JordiRemon]

Ph3 BR31 trial (Adj Durvalumab) is a negative trial ⛔️ in PDL1>25% early-stage NSCLC 🫁We discuss some reasons:
-PET in all pts
-Best quality of surgery
-Better prognostic pts…
-Did other trials overestimate Adj IO?
https://t.co/hPnXENhyiV
Tina Cascone @peters_solange @JCO_ASCO